Department of Urology, UC San Diego School of Medicine, La Jolla, CA, USA.
Urological Institute, University of Southern California, Los Angeles, CA, USA.
Eur Urol Focus. 2021 Sep;7(5):1107-1114. doi: 10.1016/j.euf.2020.10.011. Epub 2020 Nov 25.
Use of partial nephrectomy (PN) in T3 renal cell carcinoma (RCC) is controversial.
To evaluate quality outcomes of robot-assisted PN (RAPN) for clinical T3a renal masses (cT3aRM).
DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective multicenter analysis of patients with cT3aN0M0 RCC who underwent RAPN.
RAPN.
The primary endpoint was a trifecta composite outcome of negative surgical margins, warm ischemia time (WIT) ≤25 min, and no perioperative complications. The optimal outcome was defined as achieving this trifecta and ≥90% preservation of the estimated glomerular filtration rate (eGFR) and no stage upgrading of chronic kidney disease. Multivariable analysis (MVA) identified risk factors associated with lack of the optimal outcome. Kaplan-Meier analysis was conducted for survival outcomes.
Analysis was conducted for 157 patients (median follow-up 26 mo). The median tumor size was 7.0 cm (interquartile range [IQR] 5.0-7.8) and the median RENAL score was 9 (IQR 8-10). Median estimated blood loss (EBL) was 242 ml (IQR 121-354) and the median WIT was 19 min (IQR 15-25). A total of 150 patients (95.5%) had negative margins. Complications were noted in 25 patients (15.9%), with 4.5% having Clavien grade 3-5 complications. The median change in eGFR was 7 ml/min/1.72 m, with ≥90% eGFR preservation in 55.4%. The trifecta outcome was achieved for 64.3% and the optimal outcome for 37.6% of the patients. MVA revealed that greater age (odds ratio [OR] 1.06; p = 0.002), increasing RENAL score (OR 1.30; p = 0.035), and EBL >300 ml (OR 5.96, p = 0.006) were predictive of failure to achieve optimal outcome. The 5-yr recurrence-free survival, cancer-specific survival, and overall survival, were 82.1%, 93.3%, and 91.3%, respectively. Limitations include the retrospective design.
RAPN for select cT3a renal masses is feasible and safe, with acceptable quality outcomes. Further investigation is requisite to delineate the role of RAPN in cT3a RCC.
Robot-assisted partial nephrectomy in patients with stage 3a kidney cancer provided acceptable survival, functional, and morbidity outcomes in the hands of experienced surgeons, and may be considered as an option when clinically indicated.
在 T3 期肾细胞癌(RCC)中使用部分肾切除术(PN)存在争议。
评估机器人辅助 PN(RAPN)治疗临床 T3a 肾肿块(cT3aRM)的质量结果。
设计、地点和参与者:这是一项回顾性多中心分析,纳入了接受 RAPN 治疗的 cT3aN0M0 RCC 患者。
RAPN。
主要终点是手术切缘阴性、热缺血时间(WIT)≤25 分钟和无围手术期并发症的三联复合结局。最佳结局定义为达到三联复合结局,且估算肾小球滤过率(eGFR)保留率≥90%,慢性肾脏病分期无升级。多变量分析(MVA)确定了与无法达到最佳结局相关的风险因素。Kaplan-Meier 分析用于生存结局。
对 157 例患者进行了分析(中位随访 26 个月)。肿瘤大小中位数为 7.0cm(四分位距 [IQR] 5.0-7.8),RENAL 评分中位数为 9(IQR 8-10)。中位估计失血量(EBL)为 242ml(IQR 121-354),中位 WIT 为 19 分钟(IQR 15-25)。150 例(95.5%)患者切缘阴性。25 例(15.9%)患者出现并发症,4.5%患者出现 Clavien 3-5 级并发症。eGFR 的中位数变化为 7ml/min/1.72m,55.4%患者 eGFR 保留率≥90%。三联复合结局的达成率为 64.3%,最佳结局的达成率为 37.6%。MVA 显示年龄较大(优势比 [OR] 1.06;p=0.002)、RENAL 评分增加(OR 1.30;p=0.035)和 EBL>300ml(OR 5.96,p=0.006)是无法达到最佳结局的预测因素。5 年无复发生存率、癌症特异性生存率和总生存率分别为 82.1%、93.3%和 91.3%。局限性包括回顾性设计。
在经验丰富的外科医生手中,选择 T3a 肾肿块的 RAPN 是可行且安全的,具有可接受的质量结果。需要进一步研究以明确 RAPN 在 T3a RCC 中的作用。
对于 3a 期肾癌患者,机器人辅助部分肾切除术提供了可接受的生存、功能和发病率结局,在有经验的外科医生手中,当临床指征明确时,可作为一种选择。